Standard BioTools Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LAB research report →
Companywww.standardbio.com
Standard BioTools Inc. , together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics.
- CEO
- Michael Egholm
- IPO
- 2011
- Employees
- 814
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $413.79M
- P/E
- -4.37
- P/S
- 4.80
- P/B
- 0.73
- EV/EBITDA
- -2.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 48.30%
- Op Margin
- -91.02%
- Net Margin
- -109.08%
- ROE
- -20.80%
- ROIC
- -7.43%
Growth & Income
- Revenue
- $85.33M · -51.08%
- Net Income
- $-74,896,000 · 46.07%
- EPS
- $-0.20 · 61.54%
- Op Income
- $-93,305,000
- FCF YoY
- 45.55%
Performance & Tape
- 52W High
- $1.72
- 52W Low
- $0.87
- 50D MA
- $0.95
- 200D MA
- $1.23
- Beta
- 1.31
- Avg Volume
- 2.54M
Get TickerSpark's AI analysis on LAB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 6, 26 | Egholm Michael | other | 196,513 |
| Apr 6, 26 | Egholm Michael | other | 95,014 |
| Mar 20, 26 | Egholm Michael | other | 1,042,373 |
| Mar 20, 26 | Egholm Michael | other | 2,345,340 |
| Apr 6, 26 | Egholm Michael | other | 196,513 |
| Mar 20, 26 | Mackay Sean | other | 272,107 |
| Mar 20, 26 | Mackay Sean | other | 612,240 |
| Apr 6, 26 | Kim Hanjoon Alex | other | 70,183 |
| Apr 6, 26 | Kim Hanjoon Alex | other | 21,301 |
| Mar 20, 26 | Kim Hanjoon Alex | other | 323,173 |
Our LAB Coverage
We haven't published any research on LAB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LAB Report →